(Q80595803)

English

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

scientific article published on 01 September 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

myeloid leukemia

1 reference

based on heuristic

inferred from title

chronic myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Srdan Verstovsek

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

George Q. Daley

3

object named as

George Q Daley

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Jorge Cortes

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Elias Jabbour

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Susan O'Brien

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Alessandra Ferrajoli

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Charles Koller

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Yali Zhu

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Paul Statkevich

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Hagop Kantarjian

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 September 2007

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

110

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1295-1302

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein prenylation, et cetera: signal transduction in two dimensions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

RAS and leukemia: from basic mechanisms to gene-directed therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22901

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22901

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17623836%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80595803&oldid=1754966097"